SLC5A2 and type 2 diabetes mellitus: Although BMI alone cannot predict the T2DM outcomes after medical or surgical treatment modalities [25], it has been demonstrated that MBS has a more significant and durable effect on remission and improvement of T2DM compared to non-surgical treatments such as GLP-1 analog, SGLT-2 inhibitors in patients with BMI < 35 Kg/m2 [26, 27].